![Monitoring response to disease-modifying treatment in multiple sclerosis](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/thumbnail/S266704962300011X:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w96p5LBcBpyJTqfwgorxm+Ow=)
Background
Standard criteria for defining suboptimal response to disease-modifying treatment (DMT) in patients with multiple sclerosis (MS) are lacking. Decision-making on how and when DMTs should be switched is challenging. The objective of the study was to identify areas of agreement on which and when specific assessments should be conducted to monitor patient response to DMT.
Methods
A survey comprising 54 statements in nine categories was drafted by eight MS experts after gathering insight during four previous meetings of a total of 25 MS experts. For each statement, results were classified as being in general agreement (≥66.6% responded “Strongly agree” or “Agree”) or general disagreement (≥66.6% responded “Strongly disagree” or “Disagree”).
Results
The survey was sent to 790 MS neurologists, 151 of whom participated (19%), and 98 (65%) completed it. General agreement and disagreement were reached for 45 and 2 statements, respectively, on different aspects of MS management, including treatment response, MS relapses, progression, disease activity measured by imaging and biomarkers, neuropsychological evaluation, brain volume loss, DMT switches due to lack of response and applicability to clinical practice.
Conclusions
This study aims to provide guidance for the early identification of suboptimal response to DMT and for improving MS patient monitoring and treatment.